Chromatography

FastLabs Adds New COVID-19 Testing Site at Dolphin Mall

Monday, May 17, 2021 - 1:49pm

b'FastLabs, a leading rapid medical testing company, is now offering patients a site in west Miami-Dade at Dolphin Mall, located at 11401 NW 12 Street in Sweetwater.

Key Points: 
  • b'FastLabs, a leading rapid medical testing company, is now offering patients a site in west Miami-Dade at Dolphin Mall, located at 11401 NW 12 Street in Sweetwater.
  • This is the second combined location with giant REEF Technology to expand the accessibility of rapid COVID-19 testing.
  • The Dolphin Mall location will offer fast PCR tests, rapid antigen tests, rapid antibody tests, and a complete flu panel that examines over 19 common respiratory pathogens with results in minutes.\n\xe2\x80\x9cWe are very pleased to be adding this new strategic location,\xe2\x80\x9d said Dr. Raul Cruz, Chief Medical Officer at FastLabs.
  • Currently focused on COVID-19 testing and other viruses, FastLabs provides express results for those who need fast PCR and rapid testing from the convenience of their vehicles, businesses, or homes.

RotaChrom Technologies Completes CPC Separation With Food-Grade Solvents

Wednesday, May 12, 2021 - 1:31pm

The components of RotaChrom\xe2\x80\x99s system utilize a proven superior methodology of chromatography when compared to other alternative technologies on the market.

Key Points: 
  • The components of RotaChrom\xe2\x80\x99s system utilize a proven superior methodology of chromatography when compared to other alternative technologies on the market.
  • RotaChrom\xe2\x80\x99s CPC platform offers more than 90% recycling of solvents, including those in the project.
  • RotaChrom has achieved massive international success in compound separation, and it has become an industry-leading company by setting global purification standards.
  • RotaChrom\xe2\x80\x99s CPC platforms are quintessential applications when looking for a high-purity, high-capacity, and environmentally conscious solution.\n'

CDC Announces COVID-19 At-Home, Rapid Testing Approach Pioneered by eMed for International Travel to Enter the United States

Tuesday, May 11, 2021 - 8:46pm

b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.

Key Points: 
  • b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.
  • Passengers may now use eMed\'s pioneering digital-point-of-care platform, offering third-party guided and verified COVID-19 at-home rapid antigen testing with certified results in minutes and automated reporting.\nThe home test administered by eMed provides greater access to individuals needing a reliable, quick and easy rapid antigen test for COVID-19 detection.
  • "This is an important step in getting validated rapid antigen testing approved for use so international travelers entering the United States may do so with greater ease, in addition to being an important step in our collective efforts to reactivate our economy.
  • 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/cdc-announces-covid-19-at-home-r...\n'

SCIEX and Waters Corporation Collaborate to Deliver Fully Configured and Interoperable LC-MS Systems

Tuesday, May 11, 2021 - 2:00pm

\xe2\x80\x9cThrough this collaboration, we are broadening the variety of LC instruments available to our growing customer base.\xe2\x80\x9d\nSCIEX and Waters developed instrument control drivers that have been fully tested to ensure compatibility and compliance.

Key Points: 
  • \xe2\x80\x9cThrough this collaboration, we are broadening the variety of LC instruments available to our growing customer base.\xe2\x80\x9d\nSCIEX and Waters developed instrument control drivers that have been fully tested to ensure compatibility and compliance.
  • These proven drivers allow SCIEX OS software to directly control Waters ACQUITY\xe2\x84\xa2 UPLC I-Class PLUS Systems , as well as the H-Class PLUS , H-Class PLUS Bio and M-Class instruments .
  • Customers will also benefit from the commitment of both vendors to deliver coordinated service and class-leading analytical performance.
  • SCIEX will support the full customer relationship while Waters will provide direct UPLC service and support.\n\xe2\x80\x9cScientists will immediately benefit from ease of access to industry-leading UPLC systems,\xe2\x80\x9d said Jon Pratt, Senior Vice President, Waters Division.

Government of Canada increases access to COVID-19 rapid testing for workers

Friday, May 7, 2021 - 4:50pm

Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.

Key Points: 
  • Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.
  • Across the country, these rapid tests have already helped to identify and stop the transmission of over 11,000 confirmed cases of COVID-19.\nThis initiative builds on previous successful rapid testing projects supported by the Government of Canada, including through the Creative Destructions Lab Rapid Screening Consortium .
  • "\n"The Government of Canada is implementing a multi-layered strategy and response to the COVID-19 pandemic through a combination of efforts.
  • "\nRapid antigen testsalso referred to as rapid screens or rapid testsare easy to administer, and produce results in as little as 15 minutes.

Stop the spread! Could diagnostic antigen tests help control COVID-19 transmission in workplaces?

Friday, May 7, 2021 - 4:01pm

The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.

Key Points: 
  • The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.
  • It builds on the body of knowledge regarding the use of rapid antigen tests provided in ECDC reports.
  • The report shows that rapid antigen testing can help reduce the spread of the virus in high-risk indoor workplaces.
  • However, the report stresses that testing cannot replace other safety and health measures and should be used to complement them.

Kroger Health Launches Over-the-Counter Rapid Antigen Self-Test Kits

Wednesday, May 5, 2021 - 6:34pm

b'CINCINNATI, May 5, 2021 /PRNewswire/ --Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the launch of Abbott\'s BinaxNOW COVID-19 Antigen Self Test, an over-the-counter SARS-CoV-2 rapid antigen test that has received FDA Emergency Use Authorization for self-testing without the need for a prescription from a healthcare professional.

Key Points: 
  • b'CINCINNATI, May 5, 2021 /PRNewswire/ --Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the launch of Abbott\'s BinaxNOW COVID-19 Antigen Self Test, an over-the-counter SARS-CoV-2 rapid antigen test that has received FDA Emergency Use Authorization for self-testing without the need for a prescription from a healthcare professional.
  • "Abbott will continue making its BinaxNOW COVID-19 Antigen Self Test available in more national retail settings like Kroger so that people can quickly and easily find the test and get back to living their pre-pandemic lifestyles with more assurance.
  • To schedule a vaccine appointment, visit here .\nKroger Health also plans to add at-home COVID-19 antigen testing to its employer-focused health and wellness solutions.
  • Learn more at www.krogerhealth.com .\nAt The Kroger Co. (NYSE:KR), we are Fresh for Everyone and dedicated to our Purpose: ToFeed the Human Spirit.

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

Wednesday, May 5, 2021 - 1:00pm

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.

Key Points: 
  • The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.
  • Offering high sensitivity and specificity, both the Total and IgG tests which have FDA EUA and CE Mark provide public health leaders with an exceptional tool in tracking viral community spread, bolstering serological surveillance efforts, and managing patient treatment pathways.\nOrtho\'s VITROS SARS-CoV-2 Antigen Test, which achieved CE Mark in November 2020 and was authorized for use in the U.S. in January 2021, offers reliable detection of acute COVID-19 infection with high sensitivity and specificity.
  • The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.\nQuestions from laboratories, health care providers, or government officials regarding Ortho\'s COVID-19 solutions can be directed to: OrthoCOVID19Test@orthoclinicaldiagnostics.com .
  • For more information visit: https://www.orthoclinicaldiagnostics.com/global/covid19/ .\n'

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

Wednesday, May 5, 2021 - 1:00pm

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.

Key Points: 
  • The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.
  • Offering high sensitivity and specificity, both the Total and IgG tests which have FDA EUA and CE Mark provide public health leaders with an exceptional tool in tracking viral community spread, bolstering serological surveillance efforts, and managing patient treatment pathways.\nOrtho\'s VITROS SARS-CoV-2 Antigen Test, which achieved CE Mark in November 2020 and was authorized for use in the U.S. in January 2021, offers reliable detection of acute COVID-19 infection with high sensitivity and specificity.
  • The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.\nQuestions from laboratories, health care providers, or government officials regarding Ortho\'s COVID-19 solutions can be directed to: OrthoCOVID19Test@orthoclinicaldiagnostics.com .
  • For more information visit: https://www.orthoclinicaldiagnostics.com/global/covid19/ .\n'

Quidel to Present Virtually at the BofA Securities 2021 Health Care Conference

Tuesday, May 4, 2021 - 11:00pm

b"Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference, to be held virtually on Thursday, May 13, 2021.\nDouglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in a question-and-answer videoconference format.

Key Points: 
  • b"Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the BofA Securities 2021 Health Care Conference, to be held virtually on Thursday, May 13, 2021.\nDouglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present that day at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) in a question-and-answer videoconference format.
  • During the presentation, the company will discuss business and financial developments and trends.
  • An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
  • For more information about Quidel, visit quidel.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504006325/en/\n"